Bionano Genomics, Inc.【BNGO】
| Dec 31,
2018 | Dec 31,
2019 | Dec 31,
2020 | Dec 31,
2021 | Dec 31,
2022 | Dec 31,
2023 | Dec 31,
2024 |
|---|
| Net loss | -18,496,392 | -29,815,070 | -41,106,351 | -72 | -133 | -232 | -112 |
|---|
| Depreciation and amortization expense | 1 | 1 | 1 | 3 | 10 | 14 | 14 |
|---|
| Goodwill impairment | - | - | - | - | - | 77 | - |
|---|
| Inventory write-offs | 1 | - | 125,640 | - | - | - | 7 |
|---|
| Finance Lease, Right-of-Use Asset, Amortization | - | - | - | 0 | 0 | 0 | 0 |
|---|
| Accretion of interest on securities | - | - | - | - | - | 1 | 1 |
|---|
| Net realized loss on investments | - | - | - | - | -0 | -0 | -0 |
|---|
| Non-cash lease expense | - | - | - | 1 | 0 | 0 | -0 |
|---|
| Gain on lease modification | - | - | - | - | - | - | 0 |
|---|
| Stock-based compensation | 1 | 1 | 2 | 10 | 22 | 15 | 10 |
|---|
| Cost of leased equipment sold to customer | - | - | - | 1 | 0 | 0 | 0 |
|---|
| Change in fair value of contingent consideration | - | - | - | 0 | 0 | -1 | -11 |
|---|
| Fair Value, Option Liability and Notes Payable, Changes in Fair Value, Gain (Loss) | - | - | - | - | - | -1 | -8 |
|---|
| Loss on issuance of convertible debentures | - | - | - | - | - | - | -2 |
|---|
| Gain on High Trail extinguishment | -342,164 | -1,333,496 | - | -2 | - | - | 4 |
|---|
| Loss on extinguishment of convertible debentures payable | - | - | - | - | - | - | -7 |
|---|
| Disposal of internal-use software | - | - | - | - | - | - | 1 |
|---|
| Intangible assets and other long-lived assets impairment | - | - | - | - | - | - | 18 |
|---|
| Long-lived assets held for sale impairment | - | - | - | - | - | - | 0 |
|---|
| Right-of-use-asset impairment | - | - | - | - | - | - | 1 |
|---|
| Disposal of property and equipment | - | - | - | - | - | - | -1 |
|---|
| Accounts receivable | 900,119 | 2 | -2,086,927 | 0 | 3 | 2 | -4 |
|---|
| Inventory | 418,984 | 4 | 4 | 16 | 24 | 4 | 1 |
|---|
| Prepaid expenses and other current assets | -152,012 | 245,046 | 999,194 | 2 | 3 | -1 | -2 |
|---|
| Other assets | - | - | - | - | 1 | 5 | -5 |
|---|
| Accounts payable | -954,377 | 1 | -1,809,309 | 7 | 2 | -2 | -3 |
|---|
| Accrued expenses and contract liabilities | -247,402 | -73,910 | 1 | 4 | 0 | -3 | -2 |
|---|
| Net cash used in operating activities | -19,943,847 | -29 | -38,314,378 | -72 | -125 | -125 | -69 |
|---|
| Purigen acquisition, return of purchase consideration from escrow | - | - | - | - | - | 0 | - |
|---|
| Purchases of property and equipment | - | - | - | - | - | 2 | 0 |
|---|
| Purchase of available for sale securities | - | - | - | 313 | 84 | 111 | 233 |
|---|
| Sale and maturities of available for sale securities | - | - | - | - | 201 | 137 | 307 |
|---|
| Net cash provided by investing activities | -331,716 | -61,056 | -2,449,952 | -278 | 83 | 24 | 74 |
|---|
| Principal payments of financing lease liability | - | - | - | 0 | 0 | 0 | 0 |
|---|
| Proceeds from Issuance of Common Stock | - | - | - | - | - | 58 | 44 |
|---|
| Offering expenses on sale of common stock and warrants | - | - | 2 | 2 | 1 | 1 | 3 |
|---|
| Proceeds from Stock Plans | - | - | - | - | - | - | 0 |
|---|
| Proceeds from warrant and option exercises | - | - | - | - | - | - | 0 |
|---|
| Proceeds from Convertible Debt | 14 | 5 | 760,527 | - | - | - | 18 |
|---|
| Payments on High Trail notes | - | - | - | - | - | - | 61 |
|---|
| Payments on convertible debentures | - | - | - | - | - | 9 | 5 |
|---|
| Debt issuance costs on sale of convertible debentures | - | - | - | - | - | 5 | 2 |
|---|
| Payments of retirement fees for redemption of High Trail notes | - | - | - | - | - | - | 5 |
|---|
| Contingent consideration milestone payment | - | - | - | - | - | 9 | - |
|---|
| Net cash provided by (used in) financing activities | 36 | 30 | 62 | 336 | 23 | 114 | -14 |
|---|
| Effect of exchange rates on cash and cash equivalents and restricted cash | - | - | - | - | -0 | 0 | -0 |
|---|
| Net increase (decrease) in cash and cash equivalents and restricted cash | 16 | 788,644 | 21 | -14 | -19 | 13 | -9 |
|---|
| Cash paid for interest | 700,353 | 1 | 1 | 2 | 0 | 2 | 11 |
|---|
| Operating Lease, Payments | - | - | - | 0 | 2 | 3 | 3 |
|---|
| Transfer Of Instruments And Servers | - | - | - | - | - | - | 5 |
|---|
| Capital Expenditures Incurred but Not yet Paid | 3,150 | - | - | - | 0 | 0 | - |
|---|
| Debt Issuance Costs Incurred but Not yet Paid | - | - | - | - | - | 0 | - |
|---|
| Conversion Of Notes Payable Into Common Stock, Fair Value | - | - | - | - | - | 7 | - |
|---|
| Accrued liability for fees to be paid in common stock | - | - | - | - | - | - | 2 |
|---|
| Non-cash Fill-Up Amount | - | - | - | - | - | - | 0 |
|---|